Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Among authors: kulagin a. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study.
Kulagin A, Lisukov I, Ivanova M, Golubovskaya I, Kruchkova I, Bondarenko S, Vavilov V, Stancheva N, Babenko E, Sipol A, Pronkina N, Kozlov V, Afanasyev B. Kulagin A, et al. Br J Haematol. 2014 Feb;164(4):546-54. doi: 10.1111/bjh.12661. Epub 2013 Nov 22. Br J Haematol. 2014. PMID: 24261566 Free article.
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R, Brodsky RA, Ortiz S, Risitano AM, Jang JH, Hillmen P, Kulagin AD, Kulasekararaj AG, Rottinghaus ST, Aguzzi R, Gao X, Wells RA, Szer J. Peffault de Latour R, et al. Among authors: kulagin ad. Br J Haematol. 2020 Nov;191(3):476-485. doi: 10.1111/bjh.16711. Epub 2020 May 24. Br J Haematol. 2020. PMID: 32449174 Free PMC article. Clinical Trial.
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.
Kulagin AD, Ptushkin VV, Lukina EA, Davydkin IL, Korobkin AV, Shamrai VS, Konstantinova TS, Kaporskaya TS, Mitina TA, Ksenzova TI, Zuev EV, Markova OA, Gapchenko EV, Kudlay DA. Kulagin AD, et al. Ann Hematol. 2021 Nov;100(11):2689-2698. doi: 10.1007/s00277-021-04624-7. Epub 2021 Aug 16. Ann Hematol. 2021. PMID: 34398258 Free PMC article. Clinical Trial.
Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.
Petit AF, Kulasekararaj AG, Eikema DJ, Maschan A, Adjaoud D, Kulagin A, Grassi A, Fagioli F, Griskevicius L, Snowden JA, Johansson JJ, Dalle JH, Byrne J, Risitano AM, Peffault de Latour R, Dufour C. Petit AF, et al. Among authors: kulagin a. Am J Hematol. 2022 Jan 1;97(1):E1-E3. doi: 10.1002/ajh.26354. Epub 2021 Nov 28. Am J Hematol. 2022. PMID: 34553406 Free article. No abstract available.
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B, de Fontbrune FS, Lee JW, Kulagin AD, Hillmen P, Wilson A, Marantz JL, Schrezenmeier H. Höchsmann B, et al. Among authors: kulagin ad. Eur J Haematol. 2022 Sep;109(3):197-204. doi: 10.1111/ejh.13773. Epub 2022 Jun 21. Eur J Haematol. 2022. PMID: 35390189
[The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial].
Kulagin AD, Bakirov BA, Davydkin IL, Elykomov IV, Konstantinova TS, Korobkin AV, Kosinova MV, Mazurov VI, Minaeva NV, Proidakov AV, Ptushkin VV, Shatokhin YV, Lin'kova YN, Zinkina-Orikhan AV, Morozova MA. Kulagin AD, et al. Ter Arkh. 2021 Nov 15;93(11):1340-1348. doi: 10.26442/00403660.2021.11.201226. Ter Arkh. 2021. PMID: 36286657 Clinical Trial. Russian.
95 results